Hakan Bozcuk

Prof. Dr. Hakan Bozcuk


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Complementary Therapies in Medicine
Verified
Journal Article
Closed access
HBHakan Bozcuk
Hakan Bozcuk
KOK. Ozcan
K. Ozcan
CEC. Erdogan
C. Erdogan
HMH. Mutlu
H. Mutlu
MDM. Demir
M. Demir
SCS. Coskun
S. Coskun

13 November 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
HBHakan Bozcuk
Hakan Bozcuk
MAMehmet Artac
Mehmet Artac
MOMustafa Ozdogan
Mustafa Ozdogan
BSBurhan Savas
Burhan Savas

12 November 2009 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MAMehmet Artac
Mehmet Artac
HBHakan Bozcuk
Hakan Bozcuk
MPMustafa Pehlivan
Mustafa Pehlivan
SASongül Akcan
Songül Akcan
MPMustafa Pehlivan
Mustafa Pehlivan
BSBurhan Savas
Burhan Savas

1 March 2006 in Cancer Nursing
Verified
Journal Article
Closed access
HBHakan Bozcuk
Hakan Bozcuk
BDBerna Dalmis
Berna Dalmis
MSMustafa Samur
Mustafa Samur
MOMustafa Ozdogan
Mustafa Ozdogan
MAMehmet Artac
Mehmet Artac
BSBurhan Savas
Burhan Savas
Quality of life (QOL) has been shown to improve with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC), but the determinants of this improvement have not been thoroughly explored. Fifty consecutive NSCLC patients starting chemotherapy with measurable disease and with an Eastern Co-operative Oncology Group (ECOG) performance status of ≤2 were evaluated for change in QOL by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30). The status of global QOL before chemotherapy influenced the degree of change in physical functioning (F = 8.71, P =.001), global QOL (F = 23.82, P <.001), and fatigue (F = 7.92, P =.001), whereas age of the patient was again linked with the change in global QOL (F = 4.68, P =.014), and type of chemotherapy administration (1st vs. 2nd line) was associated with the change in fatigue (F = 7.82, P =.001). Our findings show that patient age and baseline QOL assessed by EORTC-QLQ-C30, but not ECOG performance status, may help predict the amount of improvement in certain aspects of QOL in patients with advanced NSCLC undergoing chemotherapy. Conversely, in this cohort, patients who are likely to have deteriorating QOL on chemotherapy may benefit from closer follow-up and nursing care to optimize supportive measures.


30 November 2014 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
HBHakan Bozcuk
Hakan Bozcuk
MYMustafa Yıldız
Mustafa Yıldız
MAMehmet Artac
Mehmet Artac
MKMurat KOÇER
Murat KOÇER
ÇKÇ. Kaya
Ç. Kaya
BSB. Savas
B. Savas